BCTX250117P1000
- 0.21
- 0.000.00%
BriaCell Therapeutics Newsroom
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
BriaCell Therapeutics Corp: INTERIM MDA EN
BriaCell Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT EN
BriaCell Therapeutics Reports Quarterly Financial Loss
10-Q: Q1 2025 Earnings Report
BriaCell Therapeutics Raises $5.55 Million in an Underwritten Offering of Share Units
Briacell Therapeutics Highlights The Infiltration Of Cancer Fighting Immune Cells Into Tumors, Using CD8 ImmunoPET Imaging Technology, In Its Poster Presentation At 2024 San Antonio Breast Cancer Symposium
BriaCell 2024 SABCS Poster Highlights Ability of Bria-IMT Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Why BriaCell Therapeutics (BCTX) Stock Is Down 40%
BriaCell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $5.5 Million Public Offering of 7.4 Million Shares at $0.75 per Share.
Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
BriaCell Therapeutics: Offering Is Expected to Close on Dec. 13 >BCT.T
BriaCell Therapeutics: Total Gross Proceeds From Offering Expected to Be Approximately $5.55M >BCT.T
BriaCell Therapeutics Intends To Offer To Sell Common Shares And Warrants In Public Offering; No Terms Disclosed
BriaCell Therapeutics Announces Proposed Public Offering
Express News | Briacell Therapeutics Announces Proposed Public Offering
Canada Net Change Percentage Gainers & Losers
HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target